The global autism spectrum disorder (ASD) treatment market was surpassed at USD 1.88 billion in 2021 and is expected to hit around USD 3.5 billion by 2030, growing at a CAGR of 7.15% from 2022 to 2030.
The autism spectrum disorder (ASD) treatment market is witnessing growth due to the rising burden of the disease. Recently, in March 2022, the updated report of the World Health Organization estimates about 1 in 100 children are suffering from ASD worldwide. According to an October 2021 article, the prevalence of ASD in the U.S. was 1.7% and 1.8% in children aged 4 and 8 years respectively. In addition, the prevalence in Europe ranged between 0.38% to 1.55%. Thus, the current evidence demonstrates the global increase in the prevalence of autism spectrum disorder over the past years.
Autism Spectrum Disorder treatment involves anticonvulsants, antipsychotics, antidepressants, and other drugs that treat symptoms of the disorder. However, currently, there are no treatment options for ASD in the market. Therefore, research and development for better treatment options are offering remunerative opportunities for market growth. For example, in May 2022, FDA granted fast-track designation to Curemark’s CM-AT indicated for ASD in 3-8 years old children. Moreover, in November 2021, Indian researchers developed the 6BIO compound, which has shown potential in improving daily activities in the pre-clinical investigation of patients with an autism spectrum disorder.
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 1.88 billion |
Revenue Forecast by 2030 | USD 3.5 billion |
Growth rate from 2022 to 2030 | CAGR of 7.15% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Type, Drug Class, Distribution Channel, Region |
Companies Covered |
Curemark LLC, Bristol-Myers Squibb, Merck & Co., Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Otsuka Pharmaceutical, Yamo Pharmaceuticals, F. Hoffmann-La Roche Ltd., and Axial Therapeutics amongst others |
The autism spectrum disorder market has been segmented based on drug class as follows:
Furthermore, the marketplace is witnessing strong public and private support through investments and funding for research and development. For instance, The Autism Impact Fund announced a capital investment in Yamo Pharmaceuticals, LLC to support phase 2 clinical studies of L1-79, indicated for ASD in November 2021. In addition, Axial Therapeutics successfully raised USD 37 million in Series C funding for AB-2004 drug candidates’ phase 2 clinical trials in children with autism in October 2021.
The space reported a significant impact of the COVID-19 pandemic which is accelerating the market growth. According to the “Coping with autism during lockdown period of the COVID-19 pandemic” published article, during the pandemic ASD patients witnessed accelerated behavioral issues and trouble in coping with mental well-being.
Strategic initiatives such as partnerships, collaborations and investment by key market players are accelerating the market growth. For instance, in July 2022, Sangamo Therapeutics and Novartis AG announced a partnership for developing Zinc Finger technology targeting genes therapies for neurological disorders such as ASD.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Autism Spectrum Disorder Treatment Market
5.1. COVID-19 Landscape: Autism Spectrum Disorder Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Autism Spectrum Disorder Treatment Market, By Type
8.1. Autism Spectrum Disorder Treatment Market, by Type, 2022-2030
8.1.1 Autistic Disorder
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Asperger's Syndrome
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Autism Spectrum Disorder Treatment Market, By Drug
9.1. Autism Spectrum Disorder Treatment Market, by Drug, 2022-2030
9.1.1. Anti-convulsants
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. SSRIs
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Anti-psychotics
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Stimulants
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Autism Spectrum Disorder Treatment Market, By Distribution Channel
10.1. Autism Spectrum Disorder Treatment Market, by Distribution Channel, 2022-2030
10.1.1. Hospital pharmacy
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail pharmacy
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online pharmacy
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Autism Spectrum Disorder Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Drug (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Drug (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Drug (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Drug (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Drug (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Drug (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Drug (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Drug (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Drug (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Drug (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Drug (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Curemark LLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eli Lilly and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Johnson & Johnson
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Otsuka Pharmaceutical
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Yamo Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. F. Hoffmann-La Roche Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms